Association of High-Level Mupirocin Resistance and Multidrug-Resistant Methicillin-Resistant Staphylococcus aureus at an Academic Center in the Midwestern United States
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Mupirocin is a topical antimicrobial used to eradicate methicillin-resistant Staphylococcus aureus (MRSA) colonization, usually in the absence of susceptibility testing. We hypothesized that high-level (HL) mupirocin resistance was associated with multidrug resistance (MDR). To this end, unique patient isolates identified at our institution during 2008 were stratified into those resistant to ≥3 non-β-lactam antimicrobial classes (MDR) and non-MDR MRSA. HL mupirocin resistance was screened by mupA PCR on all MDR isolates ( n = 191) and a 20% random sample ( n = 130) of non-MDR isolates; E-testing confirmed HL resistance. We found that among MDR isolates, 13 (6.8%) carried mupA , whereas none of the non-MDR isolates did ( P = 0.001). Thus, although the overall prevalence of HL mupirocin resistance is low among MRSA isolates at our institution, an association exists between mupA carriage and MDR. Using genotyping and antimicrobial susceptibility profiling, we identified nine HL mupirocin-resistant clones. Whereas the majority of mupA -negative MDR isolates had a health care-associated MRSA (HA-MRSA) genotype (multilocus sequence type 5 [ST5] or SCC mec type II), the majority of mupA -positive MDR isolates had a community-associated MRSA (CA-MRSA) genotype (ST8 or SCC mec type IV). However, CA- and HA-MRSA genotypes were more evenly distributed among mupA -positive isolates compared to mupA -negative MDR isolates. Thus, in Chicago, mupA is circulating among both CA- and HA-MRSA backgrounds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of the mupA gene conditions the MIC of mupirocin from 500 to >1000 mg/L [159,163,164,165,166].”
From Molecular Mechanisms of Drug Resistance in Staphylococcus aureus (2022) · cites this paper as [163]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Klevens, R. M. (2007) · JAMA · doi:10.1001/jama.298.15.1763 · Cited by 3,726
Enright, M. C., Day, N. P. J., Davies, C. E., Peacock, S. J., & Spratt, B. G. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.3.1008-1015.2000 · Cited by 3,063
Lina, G., Piemont, Y., Godail-Gamot, F., Bes, M., Peter, M.-O., Gauduchon, V., Vandenesch, F., & Etienne, J. (1999) · Clinical Infectious Diseases · doi:10.1086/313461 · Cited by 2,489
Methicillin-Resistant Staphylococcus aureus Disease in Three Communities
Fridkin, S. K., Hageman, J. C., Morrison, M., Sanza, L. T., Como-Sabetti, K., Jernigan, J. A., Harriman, K., Harrison, L. H., Lynfield, R., & Farley, M. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043252 · Cited by 1,493
Herold, B. C. (1998) · JAMA · doi:10.1001/jama.279.8.593 · Cited by 1,412
Ito, T., Katayama, Y., Asada, K., Mori, N., Tsutsumimoto, K., Tiensasitorn, C., & Hiramatsu, K. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.5.1323-1336.2001 · Cited by 963
Intranasal Mupirocin to Prevent Postoperative Staphylococcus aureus Infections
Perl, T. M., Cullen, J. J., Wenzel, R. P., Zimmerman, M. B., Pfaller, M. A., Sheppard, D., Twombley, J., French, P. P., & Herwaldt, L. A. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003069 · Cited by 799
Boyle-Vavra, S., & Daum, R. S. (2007) · Laboratory Investigation · doi:10.1038/labinvest.3700501 · Cited by 538
Self-citationKoreen, L., Ramaswamy, S. V., Graviss, E. A., Naidich, S., Musser, J. M., & Kreiswirth, B. N. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.2.792-799.2004 · Cited by 484
Diep, B. A., Chambers, H. F., Graber, C. J., Szumowski, J. D., Miller, L. G., Han, L. L., Chen, J. H., Lin, F., Lin, J., Phan, T. H., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-4-200802190-00204 · Cited by 391
Research works printed but not linked: 2
- Cadilla A. R. S. Daum and S. Boyle-Vavra. 2009. Mupirocin resistance associated with multi-drug resistant MRSA. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother. abstr. C2-140.
- Wikler M. A. 2008. Performance standards for antimicrobial susceptibility testing: 18th informational supplement vol. 28. Clinical and Laboratory Standards Institute Wayne PA.
Cited by
Molecular Mechanisms of Drug Resistance in Staphylococcus aureus
Mlynarczyk-Bonikowska, B., Kowalewski, C., Krolak-Ulinska, A., & Marusza, W. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158088 · Cited by 412
Global epidemiology of community-associated methicillin resistant Staphylococcus aureus (CA-MRSA)
Mediavilla, J. R., Chen, L., Mathema, B., & Kreiswirth, B. N. (2012) · Current Opinion in Microbiology · doi:10.1016/j.mib.2012.08.003 · Cited by 397
Progress Toward a Staphylococcus aureus Vaccine
Daum, R. S., & Spellberg, B. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cir828 · Cited by 165
Self-citation
Metadata
- Authors
- Cadilla, A., David, M. Z., Daum, R. S., & Boyle-Vavra, S.
- Affiliations
- Infectious Diseases Section, Department of Pediatrics, The University of Chicago, Chicago, Illinois
- Venue
- Journal of Clinical Microbiology
- Publisher
- American Society for Microbiology
- Published
- 2011-01
- Volume
- 49
- Issue
- 1
- Pages
- 95-100
- ISSN
- 0095-1137
- 1098-660X
- Cited by
- 52
- References
- 33
- Language
- en
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.